Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab extension study in active ankylosing spondylitis
NL-OMON44667Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Dec 2013; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON44667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44667.